Lexicon Genetics Company Profile

01:39 EST 18th November 2017 | BioPortfolio

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. We use our proprietary gene knockout technology to knock out, or disrupt, the function of genes in mice and then employ an integrated platform of advanced medical technologies to systematically discover the physiological and behavioral functions and pharmaceutical utility of the genes we have knocked out and the potential drug targets encoded by the corresponding human genes. For targets that we believe have high pharmaceutical value, we engage in programs for the discovery and development of potential small molecule, antibody and protein drugs. We have advanced drug candidates from two of these programs into human clinical trials, with drug candidates from two additional programs in preclinical development and a number of additional programs in various stages of preclinical research. We have identified and validated in living mammals, or in vivo, more than 100 targets with promising profiles for drug discovery in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. We believe that our systematic, target biology-driven approach to drug discovery will enable us to substantially expand our clinical pipeline, and we have initiated our 10TO10 program with the goal of advancing ten drug candidates into human clinical trials by the end of 2010. We are working both independently and through strategic collaborations and alliances to capitalize on our technology and drug target discoveries and to develop and commercialize drug candidates emerging from our drug discovery and development programs. We are working with Bristol-Myers Squibb Company to discover and develop new small molecule drugs in the neuroscience field. We are working with Genentech, Inc. to discover the functions of secreted proteins and potential antibody targets identified through Genentech’s internal drug discovery research, and to develop new biotherapeutic drugs based on certain targets selected from the alliance. We are working with N.V. Organon to discover, develop and commercialize new biotherapeutic drugs based on another group of secreted proteins and potential antibody targets. We are working with Takeda Pharmaceutical Company Limited for the discovery of new drugs for the treatment of high blood pressure. In addition, we have established collaborations and license agreements with other leading pharmaceutical and biotechnology companies, research institutes and academic institutions.


8800 Technology Forest Place
The Woodlands
United States of America


Phone: 281.863.3000
Fax: 281.863.8088

News Articles [489 Associated News Articles listed on BioPortfolio]

Lexicon Pharmaceuticals: from Discovery to Development

In this exclusive interview, Fintan Walton talks to Arthur Sands, President and Chief Executive Officer of Lexicon Pharmaceuticals, about the company's recent name change from Lexicon Genetics and how...

Lexicon Pharma opts to co-promote sotagliflozin in USA

Texan biotech firm Lexicon Pharmaceuticals says it has exercised its option under its collaboration and…

Jeffrey L. Wade Purchases 2,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock

Lexicon Pharmaceuticals, Inc. EVP Jeffrey L. Wade purchased 2,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average...

Lexicon Pharmaceuticals Reports Positive Phase III Data for Sotagliflozin

NewsSotagliflozin is an investigational dual SGLT1 and SGLT2 inhibitor targeting type 1 diabetes.Contributed

Lexicon Pharma opts to co─promote sotagliflozin with Sanofi in type 1 diabetes in US

Lexicon Pharmaceuticals announced that it has exercised its option under its collaboration and license agreement with Sanofi to co─promote sotagliflozin, an investigational oral dual inhibitor of so...

Lexicon's Sotagliflozin Achieves Primary Endpoint in Phase 3 Study

NewsLexicon Pharmaceuticals reports additional positive data from pivotal Phase 3 inTandem2 study of sotagliflozin.Contributed Author:

Contrasting XBiotech

XBiotech and Lexicon Pharmaceuticals are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, insti...

Lexicon announces additional positive Phase III data for diabetes drug

Lexicon Pharmaceuticals has reported additional positive data from its Phase III inTandem2 clinical trial of sotagliflozin in adult type 1 diabetes patients on a background of optimised insulin.

Drugs and Medications [0 Results]


PubMed Articles [524 Associated PubMed Articles listed on BioPortfolio]

Novel Creation of a Rum Flavor Lexicon Through the Use of Web-Based Material.

Flavor lexicons help both manufacturers and consumers communicate the intricacies of flavor nuances they experience within a product. Lexicon development typically requires the use of a trained sensor...

Lexicon Development, Consumer Acceptance, and Drivers of Liking of Quinoa Varieties.

Quinoa is becoming increasingly popular, with an expanding number of commercially available varieties. To compare the sensory properties of these quinoa varieties, a common sensory lexicon needs to be...

The Clinic Is My Laboratory: Life as a Clinical Geneticist.

Clinical genetics is the application of advances in genetics and medicine to real human families. It involves diagnosis, care, and counseling concerning options available to affected individuals and t...

Introduction to behavioral phenotypes in medical genetics.

Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound.

Our aim was to investigate whether Breast Imaging Reporting and Data System-Ultrasound (BI-RADS-US) lexicon descriptors can be used as imaging biomarkers to differentiate molecular subtypes (MS) of in...

Clinical Trials [286 Associated Clinical Trials listed on BioPortfolio]

Genetics Education: Preparing Physicians for the Future

This study examines the best way to teach genetics to family medicine residents. First year family medicine residents at the University of Toronto will be taught basic clinical genetics as...

Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics

This study will describe the experience of patients with visible physical abnormalities in the genetics clinic when they are involved in teaching others about their condition. Information ...

Virtual Reality Intervention in Cancer Genetics

The goal of this study is to evaluate a virtual reality-based intervention for training health care providers who are not genetics specialists to effectively communicate with and counsel p...

Genetics of Asthma and Bronchial Hyperresponsiveness

To investigate the genetics of asthma by reexamining a carefully characterized population of patients with asthma, and by studying their families.

Cultural Congruence in International Genetics Research

This study will explore how cultural differences influence genetics research in developing countries. Human genetics research is becoming more common in developing countries. However, when...

Companies [39 Associated Companies listed on BioPortfolio]

Lexicon Pharmaceuticals, Inc.

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has four drug candidates in mid-stage development for diabete...

Lexicon Pharmaceuticals

Lexicon Genetics is focused on the discovery and development of breakthrough treatments for human disease. We use our proprietary gene knockout technology to systematically discover the physiological ...

AccessDNA, Inc.

AccessDNA is the leading online consumer resource for genetics. The company combines high-quality content about genetics with access to, and evaluation of, relevant testing, couns...

Pharma-Lexicon International

Pharma-Lexicon International is based in Cancun, Mexico. We also have an office in East Sussex in the United Kingdom. MediLexicon has the world's largest online database of pharmaceutical and medical ...

Ambry Genetics Corporation

Ambry Genetics is a privately held healthcare company with the industry’s most comprehensive suite of genetic testing solutions, benefiting 90% of all U.S. patients covered b...

More Information about "Lexicon Genetics" on BioPortfolio

We have published hundreds of Lexicon Genetics news stories on BioPortfolio along with dozens of Lexicon Genetics Clinical Trials and PubMed Articles about Lexicon Genetics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lexicon Genetics Companies in our database. You can also find out about relevant Lexicon Genetics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record